same carrier used in its Ebola vaccine candidate and the second a glycoprotein RSV vaccine given to pregnant women that may provide infants with protective maternally-derived RSV-neutralising antibodies. The company is exploring a maternal immunisation approach with its candidate vaccine in phase II development to prevent group B streptococcus (GBS), a cause of pneumonia, meningitis and sepsis that affects about one in 2,500 births in the US. The company has 17 vaccines manufacturing sites around the world and distributes approximately 1.9 million vaccines every day to people across approximately 150 countries. The company works with its partners to accelerate development of its Ebola candidate vaccine to help prevent future disease outbreaks. Its candidate vaccine is being tested in phase II clinical trials in five countries in West Africa. Consumer Healthcare This business develops and markets products in Wellness, Oral health, Nutrition and Skin health. The company has a portfolio of brands, which include Sensodyne, Voltaren, Horlicks and Panadol. The company’s Consumer Healthcare business has a portfolio of brands. Its brands are underpinned by science-based innovation and include Panadol, Voltaren, Horlicks and Sensodyne and have developed to meet the healthcare needs of consumers worldwide. Its brands are sold in approximately 150 countries. The company’s nutrition business has a particular focus on the Indian subcontinent, where Horlicks is served as a nutritional supplement at a rate of 190 times per second, mainly to children. The core brands, including Tums, Flonase, Horlicks and Eno, have many similarities to the company’s power brands. Strategy The key elements of the company’s strategy are to grow a balanced business and product portfolio, capable of delivering sustainable sales growth; and research, develop and deliver more high quality, innovative products that offer valuable improvements in treatment for patients, consumers and healthcare providers. Significant Events In March 2016, GlaxoSmithKline and Miltenyi Biotec are partnering to develop a cell and gene therapy platform. Their collaboration would focus on discovering new chimeric antigen-receptor T-cell based therapeutics, with an eye toward optimizing manufacture and delivery to support the development of novel therapies in oncology and rare diseases. In June 2016, Regulus Therapeutics announced that it has expanded its clinical trial collaboration agreement with GlaxoSmithKline for the development of RG-101. In August 2016, GSK announced an agreement with Verily Life Sciences LLC to form Galvani Bioelectronics to enable the research, development and commercialization of bioelectronics medicines. GSK would hold a 55% equity interest in the new jointly owned company and Verily would hold 45%. History GlaxoSmithKline plc was founded in 1935.
glaxosmithkline plc (GS7:XETRA)
980 Great West Road
Brentford, TW8 9GS
Phone: 44 20 8047 5000
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for GS7.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact GLAXOSMITHKLINE PLC, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.